Life Technologies announced that it is acquiring Pinpoint Genomics and CLIA-Approved Lung Cancer Test for detecting early stage Non-Small Cell Lung Cancer Test. Pinpoint Genomics is Life Technologies’ second acquisition in the last two weeks. Earlier, Life Technologies acquired Navigenics, the personal genetics company.
Pinpoint Genomics is Mountain View, CA based company founded by two Professors, Michael Mann and David Jablons from UCSF. Lung cancer is the most deadliest cancers in US and the world, killing more people than the total deaths from breast, colon and prostate cancers combined. One of the biggest challenges in Lung Cancer diagnosis is in detecting it in early stages. The lung cancer survival rate is small because of the low lung cancer detection rate (only about 30%).
Pinpoint Genomics has developed a method for detecting ling cancer named, Pinpoint Dx Lung Assay and it has been validated in patients with Stage I, II, or III lung cancer. Pinpoint Genomics’ website says that
The Pinpoint Dx LungTM Assay is a prognostic test that differentiates between patients who are at high-, intermediate- or low-risk of dying within 5 years of their operation to remove a non-squamous non-small cell lung cancer. It was developed based on technology licensed from the Thoracic Oncology Laboratory at the University of California, San Francisco, and was validated in two independent, fully blinded clinical studies involving a total of approximately 1,500 patients.
Announcing the acquisition, Gregory T. Lucier, chairman and chief executive officer of Life Technologies, said that
We see an opportunity in lung cancer to change the treatment paradigm with more effective diagnostics,” “As Life Technologies moves further into the diagnostics space, we will focus on tests that have strong clinical utility where there is a large unmet need.
Ronnie Andrews, president of medical sciences at Life Technologies, said that
Although we’ve realized impressive gains against many forms of cancer, the survival rate for lung cancer hasn’t changed in 30 years. Half of the early-stage patients don’t survive beyond five years, a situation that could benefit from more accurate prognosis and more efficient treatment protocols.
Michael Mann, M. D., professor of cardiothoracic surgery at the UCSF and a co-founder of Pinpoint Genomics, said that
Data from the Pinpoint assay will fill a gap of insufficient prognostic information, and help physicians and their early-stage patients, who face very difficult decisions regarding post-operative therapy, to make better, individualized plans. It should therefore facilitate more effective implementation of current guidelines.